Leqembi authorization in EU is delayed for procedural issues
The EU review of Eisai’s Alzheimer’s drug lecanemab was delayed this week because of a procedural issue at the European Medicines Agency.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
